News for Tiziana Life Sciences Ltd Stock (TLSA)

Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

GlobeNewsWire • 06/05/23

Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

GlobeNewsWire • 05/25/23

Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform

GlobeNewsWire • 05/23/23

Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17

GlobeNewsWire • 05/17/23

Tiziana shares positive findings on intranasal foralumab in treating intracerebral hemorrhage

Proactive Investors • 04/27/23

Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference

GlobeNewsWire • 04/27/23

Tiziana Life Sciences provides update on development pipeline

Proactive Investors • 04/26/23

Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update

GlobeNewsWire • 04/26/23

Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

GlobeNewsWire • 04/24/23

Tiziana Life Sciences to File Alzheimer's IND for Intranasal Foralumab in Q2 2023

GlobeNewsWire • 04/20/23

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis

Accesswire • 04/19/23

Tiziana Life Sciences to develop Foralumab for type 1 diabetes

Proactive Investors • 04/18/23

Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes

GlobeNewsWire • 04/18/23

Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise

Accesswire • 04/17/23

Tiziana Life Sciences plans to investigate intranasal foralumab for the treatment of Long COVID

Proactive Investors • 04/13/23

Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID

GlobeNewsWire • 04/13/23

Tiziana Life Sciences says intranasal foralumab presented at ‘Preserving the Brain' scientific conference and exhibit in Shanghai

Proactive Investors • 04/10/23

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai

GlobeNewsWire • 04/10/23

Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference

GlobeNewsWire • 04/04/23

Tiziana Life Sciences reports positive data on intranasal anti-CD3 mAb in intracerebral hemorrhage

Proactive Investors • 04/04/23

Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage

GlobeNewsWire • 04/04/23

Tiziana Life Sciences says anti-CD3 mAb research for treatment of Alzheimer's disease to be presented at international conference

Proactive Investors • 03/31/23

Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference in Swe

GlobeNewsWire • 03/31/23

Tiziana Life Sciences plans to accept US FDA recommendations and start Phase 2 study in Q3 2023

Proactive Investors • 03/28/23

Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

GlobeNewsWire • 03/28/23